Advertisement: TTP Killer 50
15 May, 2019 - 12:15 By Kate Sweeney

Summers a man with a Mission

James Summers

Mission Therapeutics in Cambridge, whose technology promises cures for Alzheimer’s and Parkinson’s diseases, has added fresh muscle to its board with Dr James Summers becoming an independent director. 

He did his doctorate in organic chemistry at Harvard University and excelled at AbbVie and formerly Abbott.

He brings over 30 years of drug discovery and pharmaceutical research management experience to Mission’s board. 

His most recent position was as vice-president of Neuroscience Research at AbbVie, where he led drug discovery efforts in the treatment of Alzheimer’s and Parkinson’s diseases, pain, and psychiatric disorders.

He has spearheaded numerous transactions for AbbVie in the area of neurological disorders, including Mission’s collaboration with AbbVie for the development of DUB inhibitors to treat Alzheimer’s and Parkinson’s. 

Mission CEO Dr Anker Lundemose, said: “Since the start of the AbbVie collaboration in November 2018, the Mission team has already benefited from the strength of Jim’s specialist knowledge and sector experience. We believe that he will be of tremendous value to the company as we continue to progress our therapeutic pipeline.”

Dr Summers said: “In addition to its best-in-class DUB technology platform, Mission has researchers with a unique understanding of the science behind Alzheimer’s and Parkinson’s diseases. 

“I am thrilled to have the opportunity to continue to support the company as it works towards developing new treatments that positively impact the lives of patients with these debilitating diseases.”

Newsletter Subscription

Stay informed of the latest news and features